VANGUARD PLUS 5/CV-L

Composition:

Vanguard^® Plus 5/CV-L is a modified live and killed virus vaccine and bacterin combination product: it contains canine distemper virus, canine adenovirus type 2 (CAV-2), canine parainfluenza virus and a low passage, high titre canine parvovirus fraction. At the low passage level, the parvovirus concentration found in Vanguard^® Plus 5/CV-L has immunogenic properties capable of overriding interfering levels of maternal canine parvovirus (CPV) antibody. The vaccine consists of a vial containing a lyophilised vaccine plug, containing inactivated bacterin of Leptospira canicola and L. icterohaemorrhagiae. The diluent is the inactivated, adjuvanted coronavirus fraction, which is bottled separately but packaged with the other antigenic fractions

Dosage and Administration:

Use only as directed. Aseptically rehydrate the freeze-dried vaccine with the liquid preparation of inactivated CCV and shake well.

General directions: Vaccination of healthy dogs and puppies is recommended. Shake well. Aseptically administer 1 ml subcutaneously or intramuscularly.

Primary vaccination: Healthy dogs, 6 weeks of age or older, should receive 3 doses, each administered 3 weeks apart. If puppies are vaccinated at 10–12 weeks of age for the first time only two vaccinations, 3–4 weeks apart, need to be given at the veterinarian’s discretion.

Revaccination: Annual revaccination with a single dose is recommended.

Note: 

Keep out of reach of children, uninformed persons and animals.

Vaccination of pregnant bitches should be avoided. If anaphylaxis or hypersensitivity occurs following use, administer adrenaline or equivalent. Without such treatment, serious reactions may result in death. This vaccine has been shown to be efficacious but some dogs may be unable to develop or maintain an adequate immune response following vaccination if they are, for example, incubating any infectious disease, are malnourished or parasitised, or are stressed due to transport or adverse environmental conditions, or otherwise immunocompromised, or the vaccine is not administered according to label directions.

Although this product has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, notify the registration holder.

Prolonged exposure to higher temperatures may adversely affect potency.

Use entire contents when first opened.

Sterilised syringes and needles should be used to administer this vaccine. Do not sterilise with chemicals because traces of disinfectant may inactivate the vaccine.

Admixing of the vaccine with any other may render it ineffective.

Burn containers and all unused contents. Contains gentamycin as preservative

Precaution: 

Store between 2 °C and 7 °C. Do not freeze.